Latest learnings on the treatment of asymptomatic severe aortic stenosis from the EARLY TAVR

Supported by Edwards Lifesciences

Summary

At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.

In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage in 85% of patients.

The speakers also highlight the importance of patient staging and considering associated abnormalities when deciding on early treatment. The takeaway: waiting may have serious clinical and economic consequences.

This interview was filmed at EuroPCR 2025: see more videos here.